Maxemiliano V. Vargas

TL;DR: This work demonstrates that, through careful chemical design, it is possible to modify a psychedelic compound to produce a safer, non-hallucinogenic variant that has therapeutic potential.

TL;DR: In this article, a genetically encoded fluorescent sensor based on the 5-HT2AR structure was developed to detect behaviorally relevant serotonin release and correctly predicts the hallucinogenic behavioral effects of structurally similar 5-H2AR ligands.

TL;DR: In this article, the authors present an up-to-date accounting of both emerging and approved pharmacological treatments for RA, detailing their discovery, mechanisms of action, efficacy and limitations, and turn to the emerging fields of bioengineering and cell therapy to illuminate possible future targeted therapeutic options that combine material and biological sciences for localized therapeutic action with the potential to greatly reduce side effects seen in systemically applied treatment modalities.

TL;DR: In this paper, a genetically-encoded fluorescent sensor based on the 5-hydroxytryptamine 2A (5-HT2AR) structure was developed to report behaviorally-relevant serotonin release and 5-HT 2AR conformations induced by serotonergic hallucinogens.

TL;DR: It is demonstrated that ketamine and LSD, psychoplastogens from two structurally distinct chemical classes, promote sustained growth of cortical neurons after only short periods of stimulation, and it is suggested that rapidly excretedPsychoplastogen-induced cortical neuron growth can be divided into two distinct epochs.